HBV to persist although the mechanism remains unknown. This study aimed to characterize B lymphocyte subset phenotypes and measure levels of B lymphocyte-related cytokines in HCC patients. METHODS: The study population included 38 HCC patients and 30 healthy control subjects. Phenotyping of B lymphocytes was performed by flow cytometry. Serum cytokine levels were measured using a cytometric bead array immunoassay. RESULTS: The ratio of naïve (CD29 + CD27 -) to memory (CD19 + CD27 + ) B lymphocytes was significantly higher in HCC patients compared with healthy controls. The percentage of memory B lymphocytes decreased with the progression of HCC. Levels of interleukin (IL)-6 and IL-10 were significantly increased in HCC patients compared with healthy controls. CONCLUSIONS: The depletion of memory B lymphocytes may contribute to unresponsiveness to HBV or to HCC. This humoral defect might be related to raised production of IL-6 and IL-10.
Introduction
Chronic infection with the hepatitis B virus (HBV) is a major risk factor for the development of hepatocellular carcinoma (HCC) . Approximately 75% of all liver cancer deaths worldwide are attributed to HBV infection. 1 The pathogenesis of HBVrelated HCC has been extensively analysed and evidence suggests that multiple factors play a role in its development. 2 Chronic inflammation, as mediated by the host's immune system, is a major factor in the development of fibrosis and liver cell proliferation in HBV-related HCC, as is the integration of HBV DNA into the host's cellular DNA. 2 The host's immune system can either protect against or promote tumour cell growth by activating certain subsets of immune cells, resulting in the development of predominant subsets that a XD Wang and L Wang contributed equally to this work.
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can then influence the course of the disease. For example, it has been demonstrated that the cytotoxic T lymphocyte infiltration of tumours is indicative of better survival, whereas the predominance of suppressor T lymphocytes is associated with a worse outcome and lower survival rates. 3 Patients with HCC have a dysfunction of their cellular immunity and rectifying this imbalance in their immune function could be a potential treatment method for HCC. 4 HBV infection is also associated with B cell lymphoproliferative disorders, such as mixed cryoglobulinaemia and non-Hodgkin's lymphoma, 5, 6 which are, to a lesser extent, also associated with hepatitis C (HCV) infection. It is reasonable, therefore, to consider that, in addition to the host's cellular immune system, the humoral immune system is likely to be involved in HBV-related hepatocarcinogenesis.
Antigen entry into the body and the subsequent stimulation of naïve B lymphocytes into memory B lymphocytes is a complex and multistage process. Memory B lymphocytes are differentiated from naïve B lymphocytes by their activated cell surface phenotype, expression of somatically mutated immunoglobulin variable region genes, and preferential differentiation into plasma cells in vitro. 7 A common feature of somatically mutated B lymphocyte subsets is the expression of the CD27 cell surface antigen, which may represent a general marker for memory B lymphocytes in humans. 8 The presence of CD27 antigen on B lymphocytes, primed by antigenic stimulation, is essential as it promotes the differentiation of B lymphocytes via their interaction with helper T lymphocytes. 9 CD27 -B lymphocytes are defined as naïve B lymphocytes, and CD27 + B lymphocytes as memory B lymphocytes. 9 There are age-related changes in peripheral B lymphocyte subsets, with CD27 -(naïve) B lymphocytes alone produced at birth, and the number of CD27 + (memory) B lymphocytes gradually increasing throughout adolescence. 9 Some investigators have reported that human aging and virus infection lead to both quantitative and qualitative alterations in the peripheral B lymphocyte developmental system, including changes to the balance between memory and naïve B lymphocytes and their surface phenotypes. 9, 10 The association between HCV and peripheral blood B lymphocytes has been shown to potentiate viral infection of liver-derived hepatoma cells and infection of B lymphocytes with HCV promotes the development of lymphoproliferative disorders in patients with chronic HCV. 11 -13 In addition to quantitative differences, qualitative changes in the humoral immune response may also play a crucial role in determining the development of HBV-related HCC. To our knowledge, few studies have been reported concerning the humoral immune status of HCC caused by HBV.
The present study measured the proportion of peripheral blood B lymphocyte subsets and B lymphocyte-related cytokine profiles in patients with HBV-related HCC in order to: (i) characterize any functional variations in humoral immune status; and (ii) determine any correlation between the development of HCC and humoral immunological characteristics.
Patients and methods

STUDY POPULATION
Patients with HCC who were treated as inpatients at the Hepatology Unit of The Second Hospital of Jilin University (Changchun, China) from February to July 2010 were included in this prospective, observational study. Controls were recruited from among healthy subjects who were undergoing routine examination at The First XD Wang, L Wang, FJ Ji et al.
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Hospital of Jilin University. The noninvasive diagnostic criteria for HCC, as recommended by the American Association for the Study of Liver Diseases in 2005, 14 were applied. Patients were included in the study if a diagnosis of HCC was made according to clinical signs, and confirmed by helical computed tomography (CT) scan or magnetic resonance imaging (MRI) with CT/MRI angiography, ultrasound examination, liver function tests (alanine aminotransferase
[ALT], aspartate aminotransferase [AST], total bilirubin, albumin and prothrombin time) and αfetoprotein (AFP) levels. Patients with human immunodeficiency virus or with non-HBV hepatitis were excluded from the study.
The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Review Committee of The Second Hospital of Jilin University. Written informed consent was obtained from each study participant.
CLASSIFICATION OF CHRONIC LIVER DISEASE
Patients were classified according to the Child-Pugh score 15, 16 and the Barcelona Clinic Liver Cancer (BCLC) staging classifications. 17, 18 The Child-Pugh score uses five clinical measures of chronic liver disease to assess prognosis: total bilirubin, the international normalized ratio measure of prothrombin time, serum albumin, ascites and hepatic encephalopathy. Chronic liver disease is classified into Child-Pugh classes A, B or C based on the scores obtained for each of these five clinical measures: class A estimates a 1-year survival of 100% and 2year survival of 85%; class B estimates a 1year survival of 81% and 2-year survival of 57%; and class C estimates a 1-year survival of 45% and 2-year survival of 35%. The BCLC staging classification is a standardized way to assess the prognosis of patients with hepatocellular carcinoma: stage A is early stage disease; stage B is intermediate stage; stage C is advanced stage; and stage D is terminal stage.
VIROLOGICAL ASSESSMENT
Peripheral blood samples (5 ml) were taken from each subject and added to ethylenediaminetetra-acetic acid (EDTA) vacuum blood collection tubes (EDTA anticoagulant tubes; DHgate, Beijing, China), according to the manufacturer's instructions. Samples were taken before antitumour treatment was initiated.
Hepatitis B e antigen (HBeAg), was assessed using a one-step HBV test (InTec Products, Xiamen, China) according to the manufacturer's instructions. Viral load was assessed by quantifying HBV DNA with a hybridization assay using a HBV reverse transcription (RT) detection kit (Shenzhen PG Biotech, Shenzhen, China) following the manufacturer's instructions.
FLOW CYTOMETRY ANALYSIS OF CELL SURFACE MARKERS
Peripheral blood samples (5 ml) were taken into EDTA anticoagulant tubes as described above. The number of B lymphocytes in anticoagulated peripheral blood was determined using flow cytometry as follows. Briefly, 5 µl of undiluted fluorescein isothiocyanate-conjugated anti-CD19 and phycoerythrin-conjugated anti-CD27 antibodies (BD Biosciences, San Jose, CA, USA) were added to 50-µl samples of whole blood. The samples were incubated at room temperature for 1 h, following which the erythrocytes were lysed using 1 ml of fluorescence-activated cell sorting (FACS) lysing solution (eBioscience, San Diego, CA, USA) and the cells were washed twice with 2 ml of 1 × phosphate-buffered saline, pH XD Wang, L Wang, FJ Ji et al. Memory B lymphocyte depletion in hepatocellular carcinoma 7.4. 19 Isotype-matched antibodies were used as controls for all samples. All samples were analysed using a FACSCalibur flow cytometer (BD Biosciences) and FlowJo cytometry analysis software, version 5.7.2 (FlowJo, Ashland, OR, USA). At least 20 000 events per sample run were acquired. 20
ASSESSMENT OF CYTOKINE PRODUCTION
Serum samples were prepared from coagulated blood and stored at -80°C until use. Levels of T helper cytokines (interferon-γ [IFN-γ], tumour necrosis factor-α [TNF-α], interleukin [IL]-10, IL-6, IL-4 and IL-2) were determined using a cytometric bead array (CBA) immunoassay (BD Biosciences) based on the previously published method by Ahmad et al. 21 The concentration of all six cytokines in each well were calculated using CBA software, version 1.4 (BD Biosciences).
STATISTICAL ANALYSES
Statistical analyses were carried out using SPSS ® software, version 13.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . All clinical and flow cytometry data were compared using the Wilcoxon signed-rank test, the χ 2test, or an independent-sample t-test. Correlations were determined using Spearman's rank correlation coefficient (r). Results are presented as median (range) unless specified otherwise. A P-value of < 0.05 was considered to be statistically significant.
Results
A total of 38 HCC patients and 30 healthy control subjects were included in the study. Baseline demographics and clinical characteristics for patients and healthy control subjects are shown in Table 1 . Among the 38 patients with HCC, 26 had Results of the analysis of peripheral B lymphocyte subsets are shown in Figs 1 and 2. There were no significant differences in the total B lymphocyte (CD19 + ) and naïve B lymphocyte (CD19 + CD27 -) populations between the HCC and healthy control groups. The number of memory B lymphocytes (CD19 + CD27 + ) was significantly lower (P = 0.019) and the naïve/memory B ratio (CD27 -/CD27 + ) significantly higher (P = 0.009) in HCC patients than in healthy controls.
There was a significant inverse correlation between the percentage of CD19 + B lymphocytes and ALT concentration in HCC patients (r = -0.2848, P = 0.0012; Fig. 3 ). Based on the BCLC staging classification, there were significant differences in the percentage of memory B lymphocytes (CD19 + CD27 + ) across the four different BCLC stages, with the percentage of memory B lymphocytes (CD19 + CD27 + ) decreasing significantly as HCC progressed from BCLC stage A to stage D (P = 0.01) ( Fig. 4 ). There was no correlation between viral load, HBeAg status, AST level or AFP level and the percentage of naïve and memory B lymphocyte subsets (data not shown).
The serum concentrations of the six cytokines that were measured in the HCC patients and healthy control subjects are summarized in Table 2 . Concentrations of IL-6 and IL-10 were significantly higher in HCC patients than in healthy control subjects (P < 0.0001 and P = 0.0430, respectively). There were no significant between-group differences in serum TNF-α, IFN-γ, IL-2 or IL-4 concentration. There was no correlation between viral load, HBeAg status, hepatic inflammation, BCLC stage or AFP level and the cytokine concentrations (data not shown). 
Discussion
Progression of B lymphocytes to a malignant phenotype may be the consequence of additional genetic events or abnormal conditions resulting from the modification of host cell oncogenes and oncoproteins. The interaction between HBV and B lymphocytes might be explained by defects in humoral immunity in individuals who develop HCC. 22 Chi et al. 23 demonstrated that effective neutralization of HBV might be achieved by low-affinity binding of antibody to nonepitope regions of preS1. Naïve B lymphocytes can be bound to and activated by HBV capsid (core antigen), which stimulates them to become efficient antigenpresenting cells that can prime T lymphocytes and induce an effective immune response. 24 The present study demonstrated significant changes in the B lymphocyte subsets in HCC patients compared with healthy controls. Patients with HCC demonstrated extreme depletion of memory B lymphocytes, and the ratio of naïve/memory B lymphocytes was significantly increased in HCC patients compared with healthy controls. In addition, there was a significant inverse correlation between HCC disease stage and the percentage of memory B lymphocytes. Thus, the present study suggested that humoral immunity was seriously depleted with progression of HCC and that depletion of memory B lymphocytes and the imbalance of B lymphocyte subsets is a characteristic phenomenon in HBV-related HCC. It is well known that a sustained B lymphocytemediated immune response, namely a memory B lymphocyte response, against HBV provides protection against further HBV infection. 22 The present study suggested that loss of memory B lymphocytes in chronic HBV infection may play a role in the persistence of HBV infection and progression to HCC. Alternatively, the abnormalities found in the B lymphocyte subsets might reflect the direct effects of HCC.
There are limited studies evaluating the relationship between B lymphocytes and liver injury. Vallat et al. 25 showed that patients with clonal B lymphocyte proliferation in the peripheral blood and/or liver had more severe liver disease. An inverse correlation was found between the percentage of CD19 + B lymphocytes and ALT concentration in the present study, suggesting a relationship between the total number of B lymphocytes and the extent of hepatic inflammation, possibly indicating a role for the humoral immune system in inhibiting the hepatic inflammatory response. This is inconsistent with findings in autoimmune NOD.c3c4 mice where B lymphocytes appeared to promote hepatic inflammation. 26 Some cytokines, such as IL-2, IL-4, TNF-α, IL-6, IL-10 and IFN-γ, have been reported to be related to B lymphocyte development and to be altered in HBV-infected patients. 20, 27, 28 The most important B lymphocyte-related cytokines are IL-6 and IL-10. IL-6 is a pleiotropic cytokine that promotes polyclonal activation of B lymphocytes 29 and IL-10 is a potent in vitro inducer of B lymphocyte differentiation. 28 HCC patients in the present study had significantly increased levels of IL-6 and IL-10 compared with healthy controls. The humoral immunological imbalance in HCC patients might, therefore, be related to abnormally high production of IL-6 and IL-10, or to hypersensitivity of immune cells to these cytokines. 27, 28 The increased production of • Received for publication 21 July 2011 • Accepted subject to revision 22 August 2011 • Revised accepted 17 January 2012 Copyright © 2012 Field House Publishing LLP IL-6 and IL-10 in HCC patients may represent a critical mechanism of action in the abnormal humoral immune system functioning of the disease and reflect the effects of humoral abnormalities.
In summary, the present study found that B lymphocyte subsets and cytokine production displayed different patterns between HCC patients and healthy controls. The hypothesis that there is an abnormality in the memory B lymphocyte population in HBV-related HCC was examined, and a relative depletion of memory B lymphocytes was observed in HCC patients resulting in an imbalance between the B lymphocyte subsets. Alternatively, the B lymphocyte abnormalities that were observed might have been a direct consequence of the HCC disease process. These alterations in B lymphocyte subsets might also be related to the higher levels of IL-6 and IL-10 production in the HCC patients. The present findings need to be confirmed in a larger study with more extensive follow-up.
